Hepatitis C variability, patterns of resistance, and impact on therapy

Advances in Virology

Volumn 2012, Issue , 2012, Pages

  Strahotin, Cristina Simona ^a   Babich, Michael ^a  

^a ALLEGHENY HEALTH NETWORK   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 84873089377     PISSN: 16878639     EISSN: 16878647     Source Type: Journal    
DOI: 10.1155/2012/267483     Document Type: Review

References (84)

1. Wasley A., Grytdal S., Daniels D., Surveillance for acute viral hepatitis-United States, 2007. MMWR. Surveillance Summaries 2009 58 3 1 27 2-s2.0-66149093854
2. Centers for Disease Control and Prevention, Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recommendations and Reports 1998 47 RR-19 1 39
3. Alter M. J., Epidemiology of hepatitis C. Hepatology 1997 26 3 62S 65S 2-s2.0-0030955346 (Pubitemid 27388074)
4. Lavanchy D., Evolving epidemiology of hepatitis C virus. Clinical Microbiology and Infection 2011 17 2 107 115 2-s2.0-78751621217 10.1111/j.1469-0691.2010.03432.x
5. Davis G. L., Alter M. J., El-Serag H., Poynard T., Jennings L. W., Aging of hepatitis C virus (HCV)-infected persons in the United States: a multiple cohort model of HCV prevalence and disease progression. Gastroenterology 2010 138 2 513 521 2-s2.0-75149163334 10.1053/j.gastro.2009.09.067
6. Centers for Disease Control and Prevention, CDC Health Information for International Travel 2012 2012 New York, NY, USA Oxford University Press. http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases- related-to-travel/hepatitis-c.htm
7. Moradpour D., Penin F., Rice C. M., Replication of hepatitis C virus. Nature Reviews Microbiology 2007 5 6 453 463 2-s2.0-34249024924 10.1038/nrmicro1645 (Pubitemid 46780082)
8. De Beeck A. O., Dubuisson J., Topology of hepatitis C virus envelope glycoproteins. Reviews in Medical Virology 2003 13 4 233 241 2-s2.0-0038103011 10.1002/rmv.391 (Pubitemid 36875192)
9. Choo Q. L., Richman K. H., Han J. H., Berger K., Lee C., Dong C., Gallegos C., Coit D., Medina-Selby A., Barr P. J., Weiner A. J., Bradley D. W., Kuo G., Houghton M., Genetic organization and diversity of the hepatitis C virus. Proceedings of the National Academy of Sciences of the United States of America 1991 88 6 2451 2455 2-s2.0-0025968921 (Pubitemid 21916435)
10. Jubin R., Hepatitis C IRES: translating translation into a therapeutic target. Current Opinion in Molecular Therapeutics 2001 3 3 278 287 2-s2.0-0034944233 (Pubitemid 32624577)
11. Dubuisson J., Hepatitis C virus proteins. World Journal of Gastroenterology 2007 13 17 2406 2415 2-s2.0-34250681358 (Pubitemid 46929495)
12. Zeisel M. B., Barth H., Schuster C., Baumert T. F., Hepatitis C virus entry: molecular mechanisms and targets for antiviral therapy. Frontiers in Bioscience 2009 14 9 3274 3285 2-s2.0-63849140326 10.2735/3450
13. Kohaar I., Ploss A., Korol E., Mu K., Schoggins J. W., O'Brien T. R., Rice C. M., Prokunina-Olsson L., Splicing diversity of the human OCLN gene and its biological significance for hepatitis C virus entry. Journal of Virology 2010 84 14 6987 6994 2-s2.0-77953735764 10.1128/JVI.00196-10
14. Syed G. H., Amako Y., Siddiqui A., Hepatitis C virus hijacks host lipid metabolism. Trends in Endocrinology and Metabolism 2010 21 1 33 40 2-s2.0-73249118526 10.1016/j.tem.2009.07.005
15. Pawlotsky J. M., Hepatitis C virus genetic variability: pathogenic and clinical implications. Clinics in Liver Disease 2003 7 1 45 66 2-s2.0-0037301154 10.1016/S1089-3261(02)00065-X (Pubitemid 36350751)
16. Pawlotsky J. M., Hepatitis C virus population dynamics during infection. Current Topics in Microbiology and Immunology 2006 299 261 284 2-s2.0-30644457351 10.1007/3-540-26397-7-9 (Pubitemid 43086567)
17. Kuntzen T., Timm J., Berical A., Lennon N., Berlin A. M., Young S. K., Lee B., Heckerman D., Carlson J., Reyor L. L., Kleyman M., McMahon C. M., Birch C., zur Wiesch J. S., Ledlie T., Koehrsen M., Kodira C., Roberts A. D., Lauer G. M., Rosen H. R., Bihl F., Cerny A., Spengler U., Liu Z., Kim A. Y., Xing Y., Schneidewind A., Madey M. A., Fleckenstein J. F., Park V. M., Galagan J. E., Nusbaum C., Walker B. D., Lake-Bakaar G. V., Daar E. S., Jacobson I. M., Gomperts E. D., Edlin B. R., Donfield S. M., Chung R. T., Talal A. H., Marion T., Birren B. W., Henn M. R., Allen T. M., Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients. Hepatology 2008 48 6 1769 1778 2-s2.0-58149388300 10.1002/hep.22549
18. Bartels D. J., Zhou Y., Zhang E. Z., Marcial M., Byrn R. A., Pfeiffer T., Tigges A. M., Adiwijaya B. S., Lin C., Kwong A. D., Kieffer T. L., Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3.4A protease inhibitors in treatment-naïve subjects. Journal of Infectious Diseases 2008 198 6 800 807 2-s2.0-51749123143 10.1086/591141
19. Lataillade M., Chiarella J., Yang R., Schnittman S., Wirtz V., Uy J., Seekins D., Krystal M., Mancini M., McGrath D., Simen B., Egholm M., Kozal M., Prevalence and clinical significance of HIV drug resistance mutations by ultra-deep sequencing in antiretroviral-naïve subjects in the CASTLE study. PloS ONE 2010 5 6 e10952 2-s2.0-77954987724 10.1371/journal.pone.0010952
20. Rodriguez C., Chevaliez S., Bensadoun P., Ultra-deep pyrosequencing, a powerful new tool to study HBV resistance to nucleoside/nucleotide analogues, identifies preexisting HBV variants bearing resistance mutations and characterizes their on-treatment kinetics. Hepatology 2010 52 441A 442A
21. Verbinnen T., Van Marck H., Vandenbroucke I., Vijgen L., Claes M., Lin T. I., Simmen K., Neyts J., Fanning G., Lenz O., Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. Journal of Virology 2010 84 21 11124 11133 2-s2.0-77957965126 10.1128/JVI.01217-10
22. Chevaliez S., Pawlotsky J. M., Interferons and their use in persistent viral infections. Handbook of Experimental Pharmacology 2009 189 203 241 2-s2.0-61549137854 10.1007/978-3-540-79086-0-8
23. Kim C. S., Jung J. H., Wakita T., Seung K. Y., Sung K. J., Monitoring the antiviral effect of alpha interferon on individual cells. Journal of Virology 2007 81 16 8814 8820 2-s2.0-34547788145 10.1128/JVI.02824-06 (Pubitemid 47242854)
24. Porteu F., Brockhaus M., Wallach D., Engelmann H., Nathan C. F., Human neutrophil elastase releases a ligand-binding fragment from the 75-kDa tumor necrosis factor (TNF) receptor: comparison with the proteolytic activity responsible for shedding of TNF receptors from stimulated neutrophils. The Journal of Biological Chemistry 1991 266 28 18846 18853 2-s2.0-0026056106 (Pubitemid 21908161)
25. Lien E., Liabakk N. B., Johnsen A. C., Nonstad U., Sundan A., Espevik T., Polymorphonuclear granulocytes enhance lipopolysaccharide-induced soluble p75 tumor necrosis factor receptor release from mononuclear cells. European Journal of Immunology 1995 25 9 2714 2717 2-s2.0-0029093749 10.1002/eji.1830250948
26. Lantz M., Malik S., Slevin M. L., Olsson I., Infusion of tumor necrosis factor (TNF) causes an increase in circulating TNF-binding protein in humans. Cytokine 1990 2 6 402 406 2-s2.0-0025519183
27. Joyce D. A., Gibbons D. P., Green P., Steer J. H., Feldmann M., Brennan F. M., Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. European Journal of Immunology 1994 24 11 2699 2705 2-s2.0-0027959650 10.1002/eji.1830241119 (Pubitemid 24342185)
28. Tilg H., Vogel W., Dinarello C. A., Interferon- α induces circulating tumor necrosis factor receptor p55 in humans. Blood 1995 85 2 433 435 2-s2.0-0028985427
29. Neumann A. U., Zeuzem S., Ferrari C., DITTO-HCV early viral kinetics report: novel decline patterns in genotype 1 but not genotypes 2 and 3 patients treated with peg-interferon alfa-2a and ribavirin. Journal of Hepatology 2002 36 supplement 1, article 121
30. Pawlotsky J. M., Hezode C., Pellegrin B., Early HCV genotype 4 replication kinetics during treatment with peginterferon alpha-2a (Pegasys)-ribavirin combination: a comparison with HCV genotypes 1 and 3 kinetics. Hepatology 2002 36, article 291A
31. Pawlotsky J. M., Treating hepatitis C in "difficult-to-treat" patients. The New England Journal of Medicine 2004 351 5 422 423 2-s2.0-3342948412 10.1056/NEJMp048068 (Pubitemid 38988590)
32. Lau J. Y. N., Tam R. C., Liang T. J., Hong Z., Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002 35 5 1002 1009 2-s2.0-0036240477 10.1053/jhep.2002.32672 (Pubitemid 34453997)
33. Bronowicki J. P., Ouzan D., Asselah T., Desmorat H., Zarski J. P., Foucher J., Bourlière M., Renou C., Tran A., Melin P., Hézode C., Chevalier M., Bouvier-Alias M., Chevaliez S., Montestruc F., Lonjon-Domanec I., Pawlotsky J. M., Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006 131 4 1040 1048 2-s2.0-33749360440 10.1053/j.gastro.2006.07.022 (Pubitemid 44515099)
34. Contreras A. M., Hiasa Y., He W., Terella A., Schmidt E. V., Chung R. T., Viral RNA mutations are region specific and increased by ribavirin in a full-length hepatitis C virus replication system. Journal of Virology 2002 76 17 8505 8517 2-s2.0-0036333636 10.1128/JVI.76.17.8505-8517.2002 (Pubitemid 34864045)
35. Chevaliez S., Brillet R., Lázaro E., Hézode C., Pawlotsky J. M., Analysis of ribavirin mutagenicity in human hepatitis C virus infection. Journal of Virology 2007 81 14 7732 7741 2-s2.0-34447248532 10.1128/JVI.00382-07 (Pubitemid 47047859)
36. Lutchman G., Danehower S., Song B. C., Liang T. J., Hoofnagle J. H., Thomson M., Ghany M. G., Mutation rate of the hepatitis C virus NS5b in patients undergoing treatment with ribavirin mono-therapy. Gastroenterology 2007 132 5 1757 1766 2-s2.0-34247552260 10.1053/j.gastro.2007.03.035 (Pubitemid 46677946)
37. Fang S. H., Hwang L. H., Chen D. S., Chiang B. L., Ribavirin enhancement of hepatitis C virus core antigen-specific type 1 T helper cell response correlates with the increased IL-12 level. Journal of Hepatology 2000 33 5 791 798 2-s2.0-0033764610 10.1016/S0168-8278(00)80312-8
38. Feld J. J., Nanda S., Huang Y., Chen W., Cam M., Pusek S. N., Schweigler L. M., Theodore D., Zacks S. L., Liang T. J., Fried M. W., Hepatic gene expression during treatment with peginterferon and ribavirin: identifying molecular pathways for treatment response. Hepatology 2007 46 5 1548 1563 2-s2.0-36348960622 10.1002/hep.21853 (Pubitemid 350155537)
39. Tang K. H., Herrmann E., Cooksley H., Tatman N., Chokshi S., Williams R., Zeuzem S., Naoumov N. V., Relationship between early HCV kinetics and T-cell reactivity in chronic hepatitis C genotype 1 during peginterferon and ribavirin therapy. Journal of Hepatology 2005 43 5 776 782 2-s2.0-26244439300 10.1016/j.jhep.2005.05.024 (Pubitemid 41414502)
40. Feld J. J., Hoofnagle J. H., Mechanism of action of interferon and ribavirin in treatment of hepatitis C. Nature 2005 436 7053 967 972 2-s2.0-23944462641 10.1038/nature04082 (Pubitemid 41191673)
41. Ji X., Cheung R., Cooper S., Interferon alfa regulated gene expression in patients initiating interferon treatment for chronic hepatitis C. Hepatology 2003 37 3 610 621 (Pubitemid 36258783)
42. Araújo E. S., Courtouké C., Barone A. A., Hepatitis C treatment: shorter and better? Brazilian Journal of Infectious Diseases 2007 11 1 118 124 10.1590/S1413-86702007000100026 (Pubitemid 47024108)
43. Neumann A. U., Lam N. P., Dahari H., Gretch D. R., Wiley T. E., Layden T. J., Perelson A. S., Hepatitis C viral dynamics in vivo and the antiviral efficacy of interferon- α therapy. Science 1998 282 5386 103 107 2-s2.0-0032475822 10.1126/science.282.5386.103 (Pubitemid 28471138)
44. Hézode C., Forestier N., Dusheiko G., Ferenci P., Pol S., Goeser T., Bronowicki J. P., Bourlière M., Gharakhanian S., Bengtsson L., McNair L., George S., Kieffer T., Kwong A., Kauffman R. S., Alam J., Pawlotsky J. M., Zeuzem S., Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. The New England Journal of Medicine 2009 360 18 1839 1850 2-s2.0-65449171953 10.1056/NEJMoa0807650
45. Rong L., Dahari H., Ribeiro R. M., Perelson A. S., Rapid emergence of protease inhibitor resistance in hepatitis C virus. Science Translational Medicine 2010 2 1 20 2-s2.0-77953013128 10.1126/scitranslmed.3000544
46. Clavel F., Hance A. J., HIV drug resistance. The New England Journal of Medicine 2004 350 10 1023 1035 2-s2.0-1442355578 10.1056/NEJM2ra025195 (Pubitemid 38269279)
47. Pawlotsky J. M., Therapeutic implications of hepatitis C virus resistance to antiviral drugs. Therapeutic Advances in Gastroenterology 2009 2 4 205 219 2-s2.0-77950612839 10.1177/1756283X09336045
48. Adiwijaya B. S., Herrmann E., Hare B., Kieffer T., Lin C., Kwong A. D., Garg V., Randle J. C. R., Sarrazin C., Zeuzem S., Caron P. R., A multi-variant, viral dynamic model of genotype 1 HCV to assess the in vivo evolution of protease-inhibitor resistant variants. PLoS Computational Biology 2010 6 4 e1000745 2-s2.0-77954598121 10.1371/journal.pcbi.1000745
49. He Y., King M. S., Kempf D. J., Lu L., Lim H. B., Krishnan P., Kati W., Middleton T., Molla A., Relative replication capacity and selective advantage profiles of protease inhibitor-resistant hepatitis C virus (HCV) NS3 protease mutants in the HCV genotype 1b replicon system. Antimicrobial Agents and Chemotherapy 2008 52 3 1101 1110 2-s2.0-40549101840 10.1128/AAC.01149-07 (Pubitemid 351358394)
50. Lin C., Gates C. A., Rao B. G., Brennan D. L., Fulghum J. R., Luong Y. P., Frantz J. D., Lin K., Ma S., Wei Y. Y., Perni R. B., Kwong A. D., In vitro studies of cross-resistance mutations against two hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061. The Journal of Biological Chemistry 2005 280 44 36784 36791 2-s2.0-27744529265 10.1074/jbc.M506462200 (Pubitemid 41587758)
51. Lin C., Lin K., Luong Y. P., Rao B. G., Wei Y. Y., Brennan D. L., Fulghum J. R., Hsiao H. M., Ma S., Maxwell J. P., Cottrell K. M., Perni R. B., Gates C. A., Kwong A. D., In vitro resistance studies of hepatitis C virus serine protease inhibitors, VX-950 and BILN 2061: structural analysis indicates different resistance mechanisms. The Journal of Biological Chemistry 2004 279 17 17508 17514 2-s2.0-2342420348 10.1074/jbc.M313020200 (Pubitemid 38560514)
52. Tong X., Chase R., Skelton A., Chen T., Wright-Minogue J., Malcolm B. A., Identification and analysis of fitness of resistance mutations against the HCV protease inhibitor SCH 503034. Antiviral Research 2006 70 2 28 38 2-s2.0-33646036163 10.1016/j.antiviral.2005.12.003
53. Tong X., Bogen S., Chase R., Girijavallabhan V., Guo Z., Njoroge F. G., Prongay A., Saksena A., Skelton A., Xia E., Ralston R., Characterization of resistance mutations against HCV ketoamide protease inhibitors. Antiviral Research 2008 77 3 177 185 2-s2.0-38749115754 10.1016/j.antiviral.2007.11.010
54. Welsch C., Domingues F. S., Susser S., Antes I., Hartmann C., Mayr G., Schlicker A., Sarrazin C., Albrecht M., Zeuzem S., Lengauer T., Molecular basis of telaprevir resistance due to V36 and T54 mutations in the NS3-4A protease of the hepatitis C virus. Genome Biology 2008 9 1, article R16 2-s2.0-46249102168 10.1186/gb-2008-9-1-r16 (Pubitemid 351911931)
55. Zhou Y., Müh U., Hanzelka B. L., Bartels D. J., Wei Y., Rao B. G., Brennan D. L., Tigges A. M., Swenson L., Kwong A. D., Lin C., Phenotypic and structural analyses of hepatitis C virus NS3 protease Arg155 variants: sensitivity to telaprevir (VX-950) and interferon α The Journal of Biological Chemistry 2007 282 31 22619 22628 2-s2.0-34547927078 10.1074/jbc.M610207200 (Pubitemid 47267330)
56. Zhou Y., Bartels D. J., Hanzelka B. L., Müh U., Wei Y., Chu H. M., Tigges A. M., Brennan D. L., Rao B. G., Swenson L., Kwong A. D., Lin C., Phenotypic characterization of resistant Val36 variants of hepatitis C virus NS3-4A serine protease. Antimicrobial Agents and Chemotherapy 2008 52 1 110 120 2-s2.0-37849032050 10.1128/AAC.00863-07
57. Romano K. P., Ali A., Royer W. E., Schiffer C. A., Drug resistance against HCV NS3/4A inhibitors is defined by the balance of substrate recognition versus inhibitor binding. Proceedings of the National Academy of Sciences of the United States of America 2010 107 49 20986 20991 2-s2.0-78650481557 10.1073/pnas.1006370107
58. Kieffer T. L., Sarrazin C., Miller J. S., Welker M. W., Forestier N., Reesink H. W., Kwong A. D., Zeuzem S., Telaprevir and pegylated interferon-alpha-2a inhibit wild-type and resistant genotype 1 hepatitis C virus replication in patients. Hepatology 2007 46 3 631 639 2-s2.0-34548758435 10.1002/hep.21781 (Pubitemid 47436107)
59. Sarrazin C., Kieffer T. L., Bartels D., Hanzelka B., Müh U., Welker M., Wincheringer D., Zhou Y., Chu H. M., Lin C., Weegink C., Reesink H., Zeuzem S., Kwong A. D., Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir. Gastroenterology 2007 132 5 1767 1777 2-s2.0-34247594930 10.1053/j.gastro.2007.02.037 (Pubitemid 46677938)
60. Bartels D. J., DeMeyer S., Sullivan J., Summary of clinical virology findings from clinical trials of telaprevir. Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases November 2011 San Francisco, Calif, USA. Abstract 1328
61. Incivek [package insert]. Vertex Pharmaceuticals Incorporated, Cambridge, Mass, USA, 2011
62. Incivo [telaprevir]. European Medicines Agency http://www.ema.europa.eu/ docs/en-GB/document-library/EPAR-Product-Information/human/002313/WC500115529. pdf
63. Zeuzem S., Sulkowski M. S., Zoulim F., Long-term follow-up of patients with chronic hepatitis C treated with telaprevir in combination with peginterferonalfa-2a and ribavirin: interim analysis of the EXTEND study. Proceedings of the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD '10) October 2010 Boston, Mass, USA. Abstract 227
64. Sherman K. E., Sulkowski M. S., Zoulim F., Follow-up of SVR durability and viral resistance in patients with chronic hepatitis C treated with telaprevir-based regimens: interim analysis from the EXTEND study. Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases November 2011 San Francisco, Calif, USA. Abstract 248
65. Susser S., Welsch C., Wang Y., Zettler M., Domingues F. S., Karey U., Hughes E., Ralston R., Tong X., Herrmann E., Zeuzem S., Sarrazin C., Characterization of resistance to the protease inhibitor boceprevir in hepatitis C virus-infected patients. Hepatology 2009 50 6 1709 1718 2-s2.0-73149113353 10.1002/hep.23192
66. Lu L., Pilot-Matias T. J., Stewart K. D., Randolph J. T., Pithawalla R., He W., Huang P. P., Klein L. L., Mo H., Molla A., Mutations conferring resistance to a potent hepatitis C virus serine protease inhibitor in vitro. Antimicrobial Agents and Chemotherapy 2004 48 6 2260 2266 2-s2.0-2542467813 10.1128/AAC.48.6.2260-2266.2004 (Pubitemid 38691627)
67. Sulkowski M., Poordad F., McCone J., BOC combined with P/R for treatment-naïve patients with HCV genotype-1: SPRINT-2 final results. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI '11) February 2011 Boston, Mass, USA
68. Gordon S., Bacon B., Lawitz E., HCV RESPOND-2 final results: high sustained virologicresponse among genotype-1 previous non-responders and relapsers to pegIFN/RBV when re-treated with BO C + P EGINTRON/RBV. Proceedings of the 18th Conference on Retroviruses and Opportunistic Infections (CROI '11) February 2011 Boston, Mass, USA
69. Victrelis [package insert]. Merck & Company Incorporated, Whitehouse Station, NJ, USA, 2011
70. Victrelis [boceprevir]. European Medicines Agency http://www.ema.europa. eu/docs/en-GB/document-library/EPAR-Product-Information/human/002332/ WC500109786.pdf
71. Barnard R. J., Zeuzem S., Vierling J. M., Analysis of resistance-associated amino acid variants (RAVs) in non-SVR patients enrolled in a retrospective long-term follow-up analysis of boceprevir phase III clinical studies. Proceedings of the 62nd Annual Meeting of the American Association for the Study of Liver Diseases November 2011 San Francisco, Calif, USA. Abstract 164
72. Pawlotsky J. M., Treatment failure and resistance with direct-acting antiviral drugs against hepatitis C virus. Hepatology 2011 53 5 1742 1751 2-s2.0-79955103901 10.1002/hep.24262
73. Baidick C. J., Tenney D. J., Mazzucco C. E., Eggers B. J., Rose R. E., Pokornowski K. A., Yu C. F., Colonno R. J., Comprehensive evaluation of hepatitis B virus reverse transcriptase substitutions associated with entecavir resistance. Hepatology 2008 47 5 1473 1482 2-s2.0-43949100366 10.1002/hep.22211 (Pubitemid 351702731)
74. Pallier C., Castéra L., Soulier A., Hézode C., Nordmann P., Dhumeaux D., Pawlotsky J. M., Dynamics of hepatitis B virus resistance to lamivudine. Journal of Virology 2006 80 2 643 653 2-s2.0-30344463028 10.1128/JVI.80.2.643-653.2006 (Pubitemid 43062877)
75. Palleir C., Rodriguez C., Brillet R., Nordmann P., Hézode C., Pawlotsky J. M., Complex dynamics of hepatitis B virus resistance to adefovir. Hepatology 2009 49 1 50 59 2-s2.0-58949087419 10.1002/hep.22634
76. Kwo P., Lawitz J., McCone J., HCV SPRINT-1 final results: SVR 24 from a phase II study of boceprevir plus peginterferon alfa-2b/ribavirin in treatment-naïve subjects with genotype 1 chronic hepatitis C. Proceedings of the 44th Annual Meeting of the European Association for the Study of the Liver April 2009 Copenhagen, Denmark
77. McHutchison J. G., Manns M. P., Muir A. J., Terrault N. A., Jacobson I. M., Afdhal N. H., Heathcote E. J., Zeuzem S., Reesink H. W., Garg J., Bsharat M., George S., Kauffman R. S., Adda N., Di Bisceglie A. M., Telaprevir for previously treated chronic HCV infection. The New England Journal of Medicine 2010 362 14 1292 1303 2-s2.0-77950817619 10.1056/NEJMoa0908014
78. Zeuzem S., Andreone P., Pol S., REALIZE trial final results: telaprevir-based regimen for genotype 1 hepatitis C virus infection in patients with prior null response, partial response or relapse to peginterferon/ ribavirin. Proceedings of the EASL 46th Annual Meeting March 2011 Berlin, Germany
79. Jacobson I. M., McHutchison J. G., Dusheiko G., Di Bisceglie A. M., Reddy K. R., Bzowej N. H., Marcellin P., Muir A. J., Ferenci P., Flisiak R., George J., Rizzetto M., Shouval D., Sola R., Terg R. A., Yoshida E. M., Adda N., Bengtsson L., Sankoh A. J., Kieffer T. L., George S., Kauffman R. S., Zeuzem S., Telaprevir for previously untreated chronic hepatitis C virus infection. The New England Journal of Medicine 2011 364 25 2405 2416 2-s2.0-79959438789 10.1056/NEJMoa1012912
80. Ge D., Fellay J., Thompson A. J., Simon J. S., Shianna K. V., Urban T. J., Heinzen E. L., Qiu P., Bertelsen A. H., Muir A. J., Sulkowski M., McHutchison J. G., Goldstein D. B., Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance. Nature 2009 461 7262 399 401 2-s2.0-70349292099 10.1038/nature08309
81. Thompson A. J., Muir A. J., Sulkowski M. S., Ge D., Fellay J., Shianna K. V., Urban T., Afdhal N. H., Jacobson I. M., Esteban R., Poordad F., Lawitz E. J., McCone J., Shiffman M. L., Galler G. W., Lee W. M., Reindollar R., King J. W., Kwo P. Y., Ghalib R. H., Freilich B., Nyberg L. M., Zeuzem S., Poynard T., Vock D. M., Pieper K. S., Patel K., Tillmann H. L., Noviello S., Koury K., Pedicone L. D., Brass C. A., Albrecht J. K., Goldstein D. B., McHutchison J. G., Interleukin-28B polymorphism improves viral kinetics and is the strongest pretreatment predictor of sustained virologic response in genotype 1 hepatitis C virus. Gastroenterology 2010 139 1 120 129 2-s2.0-77953881002 10.1053/j.gastro.2010.04.013
82. Gane E. J., Stedman C. A., Hyland R. J., ELECTRON: once daily PSI-7977 plus RBV in HCV GT1/2/3. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver April 2012 Barcelona, Spain
83. Lawitz E., Poordad F., Kowdley K. V., A 12-week interferon-free regimen of ABT-450/r, ABT-072, and ribavirin was well tolerated and achieved sustained virologic response in 91% treatment-naïve HCV IL28B-CC genotype-1-infected subject. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver April 2012 Barcelona, Spain. Abstract 1187
84. 12 in more than 90% of treatment-naïve HCV genotype-1-infected subjects and 47% of previous non-responders. Proceedings of the 47th Annual Meeting of the European Association for the Study of the Liver April 2012 Barcelona, Spain. Abstract 1399